Adenoid Hypertrophy
Conditions
Keywords
Adenoid Hypertrophy, Periostin
Brief summary
Periostin is a matricellular protein that has been shown to be a marker of Type 2 inflammation associated with airway eosinophilia. Matricellular proteins are highly expressed at sites of injury or inflammation. Periostin involves tissue fibrosis and remodeling in the nasal mucosa in some of the otolaryngologic diseases. The up-regulation of periostin expression has been shown in allergic rhinitis, chronic rhinosinusitis with nasal polyps , and aspirin intolerant asthma. In the light of these findings the investigators aimed to evaluate the relation between adenoid hypertrophy and periostin levels.
Detailed description
A total of 40 patients-age ranged between 2 and 12 years- were planned to enroll in the study prospectively. Patients that were scheduled to undergo adenoidectomy were included in the study group (adenoid group). The control group comprised of 20 healthy children who had previously been treated for anemia in the out-patient clinic of the Pediatrics Department and were clinically healthy with normal complete blood cell counts at their follow-up visits. Serum samples were obtained from the two groups. The samples were centrifuged at 1500 g for 5 minute and stored in -80 oC for later analysis of periostin levels. Adenoid tissue and normal mucosal tissue samples were obtained from the adenoidectomy patients and stored in -80 oC for later homogenization and measurement of periostin levels.
Interventions
OTHERPeriostin level
The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
Sponsors
Bezmialem Vakif University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
Yes
Inclusion criteria
* The patients that were scheduled for adenoidectomy * Healthy subjects that had not any kind of allergy, adenoid hypertrophy symptoms
Exclusion criteria
(for adenoid group): * The subjects that had any kind of corticosteroid treatment 1 month prior to surgery, and antihistaminic treatment 2 weeks prior to surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Periostin level | 1 month | Serum periostin levels of the adenoid group and control group will be compared. |
| Adenoid tissue Periostin level | 1 month | Periostin levels of the adenoid tissue and normal mucosal healthy tissue will be compared. |
Countries
Turkey (Türkiye)
Outcome results
None listed